William Blair analyst Sami Corwin has maintained their bullish stance on PTCT stock, giving a Buy rating on November 26.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin has given his Buy rating due to a combination of factors that highlight PTC Therapeutics’ strong potential for growth. The company’s recent R&D day underscored its deep scientific expertise, showcasing its ability to efficiently develop new therapeutic candidates. This capability is expected to lead to the advancement of additional candidates into clinical trials in the near future, which could significantly enhance the company’s pipeline and future prospects.
Moreover, the successful launch of Sephience, particularly its broad acceptance across the PKU patient spectrum, is seen as a major positive. The strong demand from both prescribers and patients, along with favorable payer dynamics, positions Sephience as a potential new standard of care for PKU. This commercial success is anticipated to be a key growth driver for PTC Therapeutics, supporting the company’s path towards achieving positive cash flow in the future.
According to TipRanks, Corwin is a 4-star analyst with an average return of 11.5% and a 49.59% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Neurogene, Cabaletta Bio, and Solid Biosciences.
In another report released on November 26, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $92.00 price target.